軸性脊椎關節炎 - 機會分析與至2023年的預測
OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update
|出版日期||內容資訊||英文 199 Pages
|軸性脊椎關節炎 - 機會分析與至2023年的預測 OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update|
|出版日期: 2015年07月13日||內容資訊: 英文 199 Pages||
Ankylosing Spondylitis (AS) is an autoimmune disease that causes inflammation of the sacroiliac joint accompanied by pain and stiffness of the lower back, which typically gets better with exercise. Ankylosis (fusion) of the spine is typically a late-stage complication and has been nicknamed "bamboo spine", due to its appearance on X-ray. It is now recognized that the pathological changes leading to ankylosis develop over time, and an early stage of the disease, known as non-radiographic axial spondyloarthritis (nr-axSpA) is characterized by the same symptoms of inflammatory back pain without radiographic changes observed by X-ray. Together, AS and nr-axSpA are known as axial spondyloarthritis (axSpA). AS and nr-axSpA affect roughly 1.3 million and 700,000 individuals, respectively, in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report and the prevalence is expected to grow mainly due to changes in diagnosis rates. The anti-TNFs have been effective in treating the signs and symptoms of axSpA, however, there is a lack of effective therapeutic classes, and no treatment options for patients who have failed anti-TNF therapy, representing a key unmet need and opportunities for drug developers.